Clinical trials: Multiple Primary Neoplasm
Hereditary Angioedema
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
The objectives of the study are to: 1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE) who previously…
- Trial name
- NCT01426763
- Testing
- CINRYZE with rHuPH20
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Shire
Recurrent Glioblastoma, Brain Tumor
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
- Trial name
- NCT00503204
- Testing
- Cediranib, Lomustine
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Relapsing Multiple Sclerosis
Characterizing the Use of Ofatumumab in a Real World Setting
This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact…
- Trial name
- EAFToS (NCT05090033)
- Testing
- ofatumumab
- Where
- 7 sites in Australia
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants
Researchers are looking for a better way to treat people who have symptoms caused by hormonal changes, like those that happen in women during menopause. These symptoms can include vasomotor symptoms.
- Trial name
- NCT04889287
- Testing
- Elinzanetant (BAY3427080), Rosuvastatin
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Migraine Disorders
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
- Trial name
- NCT00240617
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 52 sites in United States
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Glaucoma, Open-Angle, Ocular Hypertension
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to…
- Trial name
- NCT06964191
- Testing
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- PolyActiva Pty Ltd
Hypogonadism, Male
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism.
- Trial name
- NCT06689085
- Testing
- Testosterone enanthate
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Halozyme Therapeutics
Dravet Syndrome, Lennox Gastaut Syndrome
Intermediate-Size Expanded Access Protocol (EAP) for LP352
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs.
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
- Trial name
- NCT06149663
- Testing
- LP352
- Where
- 22 sites in United States, Australia
- Sponsor
- Longboard Pharmaceuticals
Primary Immunodeficiency Disease
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study.
- Trial name
- NCT04842643
- Testing
- IGSC 20% infusion
- Where
- 8 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Takeda
Multiple System Atrophy, Neurodegenerative Diseases
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
This is a randomized controlled parallel Group phase I study to investigate the safety and immunological/ therapeutic activity of two new vaccines, AFFITOPE® PD01A and AFFITOPE® PD03A, given to patients with early Multiple System…
- Trial name
- AFF009 (NCT02270489)
- Testing
- AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Affiris AG
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Primary Fibromyalgia
Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia
The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo.
- Trial name
- NCT03783910
- Testing
- GRT9906
- Where
- 6 sites in United States
- Volunteers
- 90 people
- Sponsor
- Grünenthal GmbH
Primary Light-Chain Amyloidosis
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
- Trial name
- NCT07039578
- Testing
- CM336 Injection(Low dose group), CM336 Injection(High dose group)
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Keymed Biosciences Co.Ltd
Osteoarthritis, Post-traumatic Arthritis
A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement
This post-market clinical follow-up study was designed to compare hip replacement outcomes of the European Hip against 3 controls (Omniflex, Zweymuller, and Spotorno), however Omniflex did not end up being used.
- Conditions
- Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders, Avascular Necrosis
- Trial name
- NCT00208468
- Testing
- European Hip, Zweymüller, CLS Spotorno
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 317 people
- Sponsor
- DePuy International
Migraine Headache
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment.
- Trial name
- NCT00530517
- Testing
- Intraject Sumatriptan
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Zogenix, Inc.
Osteoarthritis, Arthritis
AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study
This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.
- Conditions
- Osteoarthritis, Arthritis, Avascular Necrosis, Fracture of the Femoral Neck or Head
- Trial name
- NCT01107340
- Testing
- AMIStem Hip System
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medacta International SA
Multiple Sclerosis (MS), Relapsing-Remitting MS
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
This study intends to explore evolution of MSRV expression by analyzing the levels of MSRV transcripts in blood, as well as the levels of the MSRV-Env protein in serum of MS patients.
- Conditions
- Multiple Sclerosis (MS), Relapsing-Remitting MS, Primary Progressive MS, Secondary Progressive MS
- Trial name
- LOMBARD (NCT01804647)
- Testing
- No study treatments administered - blood draws only
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 58 people
- Sponsor
- GeNeuro Innovation SAS
Primary Immunodeficiency Diseases (PID)
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
In this study, Japanese participants with primary immunodeficiency diseases were treated with Immune Globulin Subcutaneous (Human), 20% solution, (IGSC, 20%).
- Trial name
- NCT04346108
- Testing
- Immune Globulin Intravenous (IGIV), Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
- Where
- 8 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Baxalta now part of Shire
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation